Erythromycin Ophthalmic Ointment USP, 0.5%

Manufacturer
Sentiss Pharmaceuticals LLC | SENTISS AG | Ophtapharm AG
Effective date
2026-03-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 22:12:17

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure11 sections

Indications and uses

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrh...

Dosage and administration

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Opthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. Th...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Sterile

Rx only

DESCRIPTION:

DESCRIPTION SECTION

Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3- O-methyl-α-L- ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D- xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione)) is an antibiotic produced from a strain of Streptomyces erythraeus.

It has the following structural formula:

Structural FormulaStructural Formula

Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

MICROBIOLOGY SECTION

Microbiology:Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitroand in clinical infections:

Streptococcus pyogenes(group A β-hemolytic)

Alpha-hemolytic streptococci (viridans group)

Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)

Streptococcus pneumoniae

Mycoplasma pneumoniae(Eaton Agent, PPLO)

Haemophilus influenzae(not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)

Treponema pallidum

Corynebacterium diphtheriae

Neisseria gonorrhoeae

Chlamydia trachomatis

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeaeor C. trachomatis.

The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeaeis not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General:The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

INFORMATION FOR PATIENTS SECTION

Information for Patients:Avoid contaminating the applicator tip with material from the eye, fingers, or other source.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility:Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

PREGNANCY SECTION

Pregnancy:Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers:Caution should be exercised when erythromycin is administered to a nursing woman.

GERIATRIC USE SECTION

Geriatric Use:No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Opthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection.

For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Sterile Erythromycin Ophthalmic Ointment USP, 0.5% is available as follows:

3.5 g (1/8 oz) sterile tamper-resistant tube (NDC 70244-031-02)

Carton of fifty (50) Unit Dose 1 g tube (NDC 70244-031-01)

STORAGE AND HANDLING SECTION

STORAGE:Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Avoid excessive heat.

Protect from freezing.

Distributed by:

Sentiss Pharmaceuticals, LLC..

San Clemente, CA 92672

Manufactured by:

Ophtapharm AG, Riethofstrasse 1, Hellingen,

8442, Switzerland (CHE) for Sentiss

Made in Switzerland

83081200 Rev. 03/26

Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70244-031-02

ERYTHROMYCIN OPHTHALMIC

OINTMENT USP, 0.5%

Rx only Sterile Net Wt. 3.5 g (1/8 oz.)

02 label02 label

NDC 70244-031-01

ERYTHROMYCIN OPHTHALMIC

OINTMENT USP, 0.5%

Rx only Sterile Net Wt. 1 g

Container label 01Container label 01

Principal Display Panel Text for Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

3.5 g NDC 70244-031-02

ERYTHROMYCIN OPHTHALMIC

OINTMENT USP, 0.5%

Rx only Sterile Net Wt 3.5 g (1/8 oz.)

02 container02 container

1 g NDC 70244-031-01

ERYTHROMYCIN OPHTHALMIC

OINTMENT USP, 0.5%

Rx only Sterile Net Wt 1 g

container label 01container label 01

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310149erythromycin 0.5 % (5 MG/GM) Ophthalmic OintmentPSN3
310149erythromycin 0.005 MG/MG Ophthalmic OintmentSCD3
310149erythromycin 0.5 % Ophthalmic OintmentSY3
310149erythromycin 5 MG per GM Ophthalmic OintmentSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ERYTHROMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d329c2e1-5ae8-4e64-aea0-77ecea3fa1abProduct name320250717
3b331500-3b74-bd2b-fede-d46839f2f4d5Product name620240313
fdae2630-eae0-4769-abfd-8f33d5b771b4Product name320240202
8c898317-b543-1e4e-254f-84cec2f3f57eProduct name220191002
64ae94c0-3212-d73a-92da-9e6dd85c6ebeProduct name220180118
edcfa1cf-915f-1a4c-d0aa-508cc66e70d9Product name220170816
ad75fcfd-a339-42a1-9c60-43ba2c654cfaProduct name120170810
57850177-5927-151f-e1fa-7e2ca47f81e5Product name120140508
8ee71591-1d8f-e24e-242b-bfef131e3168Product name120140508
bff5cf99-0f45-fa15-2a76-b160c3c4cc3cProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70244-031-01Erythromycin1 g in 1 TUBEOINTMENT13
70244-031-01Erythromycin50 in 1 CARTONOINTMENT503
70244-031-02Erythromycin3.5 g in 1 TUBEOINTMENT3.53
70244-031-02Erythromycin1 in 1 CARTONOINTMENT13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70244-03170244-031-02, 70244-031-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
MINERAL OILT5L8T28FGPIACT
PETROLATUM4T6H12BN9UIACT
ERYTHROMYCIN63937KV33DACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064030-001ERYTHROMYCINERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064030-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1884e616aacf4f…
2026-08-18 06:07:402026-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183f01610625f2…
2019-09-15 20:21 UTC2019-09A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18b00525d2431f…
2019-07-19 19:46 UTC2019-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183f0d92c62455…
2023-05-13 08:27 UTC2023-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18053a50430f4f…
2023-01-26 05:58 UTC2023-01A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064030-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064030-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064030-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064030-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064030-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064030-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064030-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064030-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064030-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064030-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064030-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064030-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064030-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064030-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064030-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064030-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064030-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064030-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064030-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064030-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064030-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064030-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064030-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064030-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064030-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064030-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064030-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064030-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064030-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064030-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064030-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064030-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064030-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064030-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064030-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064030-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064030-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064030-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064030-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064030-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ErythromycinERYTHROMYCINSentiss Pharmaceuticals LLC4da0e351-383f-55da-e063-6394a90a8eba2026-03-31Adverse reactionsExact identifier
ndc (package): 70244-031-02
ndc (package): 70244-031-01
ndc (product): 70244-031
ndc11 (package): 70244003102
ndc11 (package): 70244003101
spl id: 4e5551f0-ee9f-ff52-e063-6294a90ad787
spl set id: 4da0e351-383f-55da-e063-6394a90a8eba

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.